Intercalated chemotherapy and erlotinib: a viable first-line option for patients with advanced NSCLC? - authors' reply

Lancet Oncol. 2013 Oct;14(11):e438-e439. doi: 10.1016/S1470-2045(13)70434-0.

Authors

Tony S K Mok¹, Yi-Long Wu²

Affiliations

¹ The Chinese University of Hong Kong, Sir YK Pau Cancer Center, State Key Laboratory of Southern China, Prince of Wales Hospital, Hong Kong, China. Electronic address: tony@clo.cuhk.edu.hk.
² Guangdong Lung Cancer Institute, Guangdong General Hospital, Guangdong, China.

PMID: 24079868
DOI: 10.1016/S1470-2045(13)70434-0

No abstract available

Publication types

Letter
Comment

MeSH terms

Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Carcinoma, Non-Small-Cell Lung / drug therapy*
Female
Humans
Lung Neoplasms / drug therapy*
Male